Jasper Therapeutics (JSPR) Free Cash Flow (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Free Cash Flow of -$21.9 million for Q4 2025, down 3.19% year-over-year from -$22.6 million in Q4 2024, and down 28.9% quarter-over-quarter from -$17.0 million in Q3 2025.
Jasper Therapeutics (JSPR) Free Cash Flow (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$21.9 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 3.19% year-over-year to -$21.9 million; the TTM figure through Dec 2025 stood at -$77.2 million (down 22.26% YoY), while the FY2025 annual figure was -$77.2 million, down 22.26% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$21.9 million, down from -$17.0 million in the prior quarter.
- The five-year high for Free Cash Flow was -$5.5 million in Q2 2021, with the low at -$22.6 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$13.8 million (2022), against an average of -$13.8 million.
- Peak annual rise in Free Cash Flow reached 34.58% in 2021, while the deepest fall reached 3063.65% in 2021.
- Jasper Therapeutics' Free Cash Flow stood at -$15.3 million in 2021, then advanced by 12.53% to -$13.4 million in 2022, then retreated by 28.02% to -$17.1 million in 2023, then dropped by 23.94% to -$21.2 million in 2024, then dropped by 3.19% to -$21.9 million in 2025.
- Business Quant data shows JSPR's Free Cash Flow at -$21.9 million in Q4 2025, -$17.0 million in Q3 2025, and -$15.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 477.44 Mn |
| 10 | Jasper Therapeutics | 20.09 Mn | 20.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.91 Mn |
| Dec 31, 2025 | -21.91 Mn |
| Sep 30, 2025 | -16.99 Mn |
| Sep 30, 2025 | -16.99 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Mar 31, 2025 | -22.55 Mn |
| Mar 31, 2025 | -22.55 Mn |
| Dec 31, 2024 | -21.23 Mn |
| Dec 31, 2024 | -21.23 Mn |
| Sep 30, 2024 | -14.70 Mn |
| Sep 30, 2024 | -14.70 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Mar 31, 2024 | -15.73 Mn |
| Mar 31, 2024 | -15.73 Mn |
| Dec 31, 2023 | -17.13 Mn |
| Dec 31, 2023 | -17.13 Mn |
| Sep 30, 2023 | -11.60 Mn |
| Sep 30, 2023 | -11.60 Mn |